Abbott enters mitral valve replacement market via $250mm Tendyne buy
Executive Summary
Abbott Laboratories Inc. acquired the portion of private device company Tendyne Holdings Inc. (minimally invasive mitral valve replacement therapies) that it doesn’t already own, paying $225mm in cash up front, and a potential $25mm in earn-outs contingent on regulatory milestones.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice